SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
08 juin 2022 10h00 HE | Sermonix Pharmaceuticals Inc.
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
31 mai 2022 15h25 HE | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
13 déc. 2021 10h00 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant
16 août 2021 10h00 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
17 mai 2021 10h19 HE | Sermonix Pharmaceuticals LLC
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclibStudy results demonstrate...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
13 oct. 2020 09h30 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada
30 sept. 2020 10h00 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting
18 juin 2020 10h06 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, June 18, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-focused oncology products in the...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting
25 sept. 2019 10h00 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
23 sept. 2019 10h01 HE | Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...